Latest Conference Articles

Bristol Myers Squibb’s Director of Business Operations for MSAT, Carl Allenspach, Highlights Collaboration and Interactive Exchange at INTERPHEX

April 2nd 2024

Carl Allenspach, director of business operations, manufacturing, science, and technology organization at Bristol Myers Squibb discusses the interactive and collaborative important of INTERPHEX.

J.P. Morgan Losing Weight

February 2nd 2024

Given its positioning at each new year’s commencement, the J.P. Morgan Healthcare conference helps establish the tone with which the pharmaceutical industry is viewed.

A Look at New Airlift Technology in Single-Use Bioreactors Systems

December 11th 2023

Pharmaceutical Technology Europe® spoke with Fiona Bellot, sales director, Cellexus BioreactorSystems, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.

Democratizing GMP Manufacturing for the New Therapeutic Pipeline

November 21st 2023

PharmTech Europe discusses technology that enables the “democratization” of mRNA manufacturing with Scott Ripley, general manager, Nucleic Acid Therapeutics and Precision Nanosystems, Cytiva, at the 11th International mRNA Health Conference in Berlin, Germany.

mRNA Advances Allow Drug Development Focus on Rare Diseases (Part Two)

November 20th 2023

In part two of an interview with Thomas Langenickel, MD, chief medical officer at Ethris, Langenickel highlights the challenges in developing mRNA therapeutics for pulmonary diseases.

Discussing the Origins of the mRNA Therapeutics Field (Part Two)

November 17th 2023

Andy Geall, co-founder and chief development officer at Replicate Bioscience continues the discussion on the development history of mRNA therapeutics.

mRNA Advances Allow Drug Development Focus on Rare Diseases (Part One)

November 14th 2023

A discussion with Thomas Langenickel, MD, chief medical officer at Ethris, shines a light on how advances made with mRNA technology are also advancing the industry’s ability to focus on treatment of rare diseases, such as rare lung diseases.

Discussing the Origins of the mRNA Therapeutics Field (Part One)

November 9th 2023

Andy Geall, co-founder and chief development officer at Replicate Bioscience, discusses the historical context and buildup of the mRNA therapeutics field.

The Need for New Bioanalysis Technology (AAPS PharmSci 360)

November 7th 2023

Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation highlights the company’s motivation behind their new bioanalysis kit for oligonucleotides.

mRNA: Unparalleled Potential as a Drug

November 7th 2023

Chris Spivey, editorial director for Pharmaceutical Technology®, discusses mRNA advances and the background for the leading scientific conference for the field, with host and co-organizer CureVac CEO Dr. Alexander Zehnder.